You are here

Monjuvi

With Jakafi's patent cliff looming, Incyte looks to 2025 launches to bulk up revenue by decade's end

Fierce Pharma

Wed, 10/30/24 - 11:42 am

graft vs host disease

follicular lymphoma

squamous cell anal carcinoma

Armed with Phase III win, Incyte eyes label expansion for Monjuvi

Clinical Trials Arena

Fri, 08/16/24 - 11:19 am

clinical trials

relapsed or refractory follicular lymphoma

OptumRx's 3 recently approved drugs to watch

Beckers Hospital Review

Tue, 09/22/20 - 10:15 pm

FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population

MedCity News

Mon, 08/3/20 - 10:14 am

diffuse large B-cell lymphoma